NEKTAR THERAPEUTICS

(c) Director and Section 16 Officer Trading Arrangements and Policies

Howard W. Robin, our President and Chief Executive Officer, entered into a pre-arranged stock trading plan intended to satisfy the affirmative defense of Rule10b5-1(c) under the Exchange Act on March 13, 2026. Mr. Robin’s trading plan provides for the sale of up to an aggregate 20,000 shares of the Company’s common stock (comprised of previously vested restricted stock), which plan has aduration of the earlier of March 19, 2027, or such date upon which all transactions are completed or expire without execution.

Jonathan Zalevsky, Ph.D., our Chief Research and Development Officer, previouslyen tered into a pre-arranged stock trading plan intended to satisfy the affirmative defense of Rule10b5-1(c) under the Exchange Act on May 16, 2025, which provided for the sale of up to an aggregate 6,073 shares of the Company’s common stock (comprised of previously vested restricted stock units and exercised stock options). The plan terminated on January 20, 2026 upon completion of all transactions thereunder.

Dr. Zalevsky alsoen tered into a pre-arranged stock trading plan intended to satisfy the affirmative defense of Rule10b5-1(c) under the Exchange Act on March 13, 2026. Dr. Zalevksy’s trading plan provides for the sale of up to an aggregate 11,219 shares of the Company’s common stock (comprised of previously vested restricted stock units), which plan has adurationof the earlier of April 15, 2027, or such date upon which all transactions are completed or expire without execution.

In the fiscal quarter ended March 31, 2026, no other directors or Section 16 officers of the Company adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408 of Regulation S-K.